Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

Cantor Fitzgerald reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...